CDK ASSOCIATES, L.L.C. 4
4 · Strongbridge Biopharma plc · Filed Sep 21, 2020
Insider Transaction Report
Form 4
CDK ASSOCIATES, L.L.C.
10% Owner
Transactions
- Purchase
Ordinary Shares, $0.01 par value
2020-09-17$2.25/sh+1,473,377$3,315,098→ 8,054,682 total - Purchase
Ordinary Shares, $0.01 par value
2020-09-18$2.20/sh+6,000$13,200→ 8,060,682 total
Footnotes (2)
- [F1]Following the transactions reported herein, these shares represent (a) 7,529,834 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 530,848 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation.
- [F2]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.24 to $2.25 per share, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price.